Up to 20,000 prostate cancer diagnoses could have been missed during the pandemic, research suggests
Analysis of 24million patient records since 2020 found tens of thousands of men have missed potentially life-saving cancer diagnoses. (Stock Image general view of hospital ward.) (Source: the Mail online | Health)
Source: the Mail online | Health - March 17, 2024 Category: Consumer Health News Source Type: news

Targeted radiopharmaceuticals offer new hope for longer'healthspans '
Mark Crockett, MD, chief medical officer at TeleDaaS.Americans today can expect to live long lives. However, increased longevity has brought on a troubling rise in chronic disease, diminishing the quality of life later in life. A 2018 study from the U.S. Centers for Disease Control and Prevention (CDC) found that more than a quarter of U.S. adults now battle multiple chronic conditions, up from 22% in 2001. We may be living longer, but more Americans struggle through these extra years in poor health — presenting a pressing need to extend not just lifespans but “healthspans.” An emerging field of precision radiopharm...
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Tags: Molecular Imaging Source Type: news

Clarity reports on third cohort in copper theranostic trial
Clarity Pharmaceuticals has completed its third cohort in the theranostic SECuRE trial evaluating copper-64 (Cu-64) and copper-67 (Cu-67) sarcophagine chelator technology in patients with metastatic castration-resistant prostate cancer. In this phase I/IIa trial of Cu-64 for the diagnostic and Cu-67 for the therapeutic, the company noted no dose-limiting toxicities in cohort 3, and an overall safety review of all cohorts 1, 2, and 3 also showed favorable safety profiles. Cohort 3 participants had the highest number of pretreatments prior to entering the study across all cohorts, with most patients receiving five or more l...
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Nuclear Radiology Radiation Oncology Source Type: news

Black Men Face Highest Incidence of Prostate Cancer in the U.K.
THURSDAY, March 14, 2024 -- Among primary care patients in the United Kingdom, the incidence of prostate cancer with an elevated prostate-specific antigen (PSA) result is higher among Black men than White or Asian men, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 14, 2024 Category: Pharmaceuticals Source Type: news

Getting Prostate Cancer Drugs Sooner; Limiting Toxic Emissions; FTC Sues 'Charity'
(MedPage Today) -- Progression-free survival reasonably predicts overall survival in advanced prostate cancer and could bring new therapies to patients about 2 years faster if used as the primary endpoint in clinical studies. (University College... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 14, 2024 Category: Hematology Source Type: news

CPDC wraps up trial of PSMA-PET radiotracer
Canadian corporation the Centre for Probe Development and Commercialization (CPDC) has closed its phase III trial of F-18 PSMA-1007, a PET radiotracer designed for prostate cancer imaging. The closure of the trial is a significant milestone on the path to submission for Canadian regulatory approval, with submission of the trial results to Health Canada expected later this year, the CPDC said. The CPDC has licensed F-18 PSMA-1007 from ABX Advanced Biochemical Compounds of Radeberg, Germany, and holds the exclusive license to develop, manufacture, and distribute the imaging agent in Canada. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Enhancing Prostate Cancer Screening: AI, Imaging and Clinical Innovations, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the evolution of prostate cancer screening and the shift to magnetic resonance imaging (MRI)-based diagnostic tools for more accurate screening. Attendees will learn about the contribution of medical imaging for better management of patient diagnosis,... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 13, 2024 Category: Pharmaceuticals Source Type: news

Drug Discount May Boost Adherence to Prostate Cancer Therapy Drug Discount May Boost Adherence to Prostate Cancer Therapy
The 340B drug discount program was not associated with oral specialty drug use in advanced prostate cancer but was linked to better adherence to medication in more vulnerable patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

'Cancer docs said I had two years to live - I'm still here 13 years later'
EXCLUSIVE: Prostate cancer patient Gary Hooker shared his remarkable story as research found trials of new drugs could be accelerated to save more lives. (Source: Daily Express - Health)
Source: Daily Express - Health - March 9, 2024 Category: Consumer Health News Source Type: news

Red flag sign at night could mean you have higher risk of killer disease
Many of us experience poor sleep occasionally but in some cases it could mean you are at greater risk for prostate cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - March 7, 2024 Category: Consumer Health News Source Type: news

MRgFUS shows promise in treating prostate cancer
MRI-guided focused ultrasound (MRgFUS) therapy can successfully treat prostate cancer for those at intermediate risk, a study published March 5 in Radiology found. Researchers led by Sangeet Ghai, MD, from the University of Toronto in Canada found that MRgFUS led to no adverse effects and negative follow-up results two years after treatment. “Additionally, there was no significant decline in quality of life per the validated questionnaires,” Ghai and colleagues wrote. MRgFUS allows for clinicians and interventional radiologists to accurately target localized areas deemed to be clinically significant, including for t...
Source: AuntMinnie.com Headlines - March 7, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties MRI Genitourinary Radiology Source Type: news

Telix to buy ARTMS in $82M deal
Telix Pharmaceuticals has entered an agreement to acquire Canadian diagnostic imaging isotopes company ARTMS for $82 million. Under the agreement, Telix will take on ARTMS’ cyclotron-based isotope production platform, manufacturing plant, and stockpile of ultrapure rare metals such as zinc-68, which is irradiated to produce gallium-68. The companies have been collaborating since 2020 to develop higher curie-scale production of Illuccix, a PET radiotracer injection kit used for prostate cancer imaging. ARTMS is based in Burnaby, British Columbia, and is a privately held spin-off company of TRIUMF, Canada's particle acce...
Source: AuntMinnie.com Headlines - March 6, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Namibia: Prostate Cancer the Leading Cancer in Namibia
[New Era] The International Agency for Research on Cancer (IARC), through the Global Cancer Observatory (GCO), recently announced that prostate cancer is Namibia's leading malignancy. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 5, 2024 Category: African Health Tags: Health and Medicine Namibia Southern Africa Source Type: news

My prostate tumour had no symptoms. If my wife hadn't made me see a doctor, it could have been fatal, reveals Steve Rider
Last autumn, after a 45-year career in sports broadcasting 'without a single day off through ill health', Steve Rider learned he had ­prostate cancer - and it could kill him if he didn't act fast. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2024 Category: Consumer Health News Source Type: news

Steve Rider's prostate tumour had no symptoms. If his wife hadn't made him see a doctor, it could have been fatal
Last autumn, after a 45-year career in sports broadcasting 'without a single day off through ill health', Steve Rider learned he had ­prostate cancer - and it could kill him if he didn't act fast. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2024 Category: Consumer Health News Source Type: news